Results 221 to 230 of about 25,976,263 (323)
THE FULL C* -ALGEBRA OF THE FREE GROUP ON TWO GENERATORS
Man-Duen Choi
semanticscholar +1 more source
Combining PTEN protein assessment and transcriptomic profiling of prostate tumors, we uncovered a network enriched in senescence and extracellular matrix (ECM) programs associated with PTEN loss and conserved in a mouse model. We show that PTEN‐deficient cells trigger paracrine remodeling of the surrounding stroma and this information could help ...
Ivana Rondon‐Lorefice +16 more
wiley +1 more source
Lunch Provision, Consumption and Plate Waste in Early Years Settings in Sheffield. [PDF]
Wall CJ, Pearce J.
europepmc +1 more source
Next‐generation proteomics improves lung cancer risk prediction
This is one of very few studies that used prediagnostic blood samples from participants of two large population‐based cohorts. We identified, evaluated, and validated an innovative protein marker model that outperformed an established risk prediction model and criteria employed by low‐dose computed tomography in lung cancer screening trials.
Megha Bhardwaj +4 more
wiley +1 more source
Postoperative opioid-free analgesia with acetaminophen and its impact on pain and postoperative nausea and vomiting following arthroscopic rotator cuff repair: a single-center retrospective study. [PDF]
Okizuka M +6 more
europepmc +1 more source
Groups with the same lower central sequence as a relatively free group
G. Baumslag
semanticscholar +1 more source
Potential therapeutic targeting of BKCa channels in glioblastoma treatment
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak +4 more
wiley +1 more source
Celiac Disease in Children with Idiopathic Nephrotic Syndrome-A Retrospective Cohort Study. [PDF]
Ozimek A +3 more
europepmc +1 more source
Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute +17 more
wiley +1 more source

